Anagliptin protects neuronal cells against endogenous amyloid β (Aβ)-induced cytotoxicity and apoptosis

References

• Nalivaeva NN, Turner AJ. Targeting amyloid clearance in Alzheimer’s disease as a therapeutic strategy. Br J Pharmacol [In press]. 2019.
   PubMed Web of Science ®Google Scholar
• Li NM, Liu KF, Qiu YJ, et al. Mutations of beta-amyloid precursor protein alter the consequence of Alzheimer’s disease pathogenesis. Neural Regen Res. 2019;14:658–665.
   PubMed Web of Science ®Google Scholar
• Cho YY, Kwon OH, Park MK, et al. Elevated cellular cholesterol in familial Alzheimer’s presenilin 1 mutation is associated with lipid raft localization of β-amyloid precursor protein. PLoS One. 2019;14:e0210535.
   PubMed Web of Science ®Google Scholar
• Aso E, Juvés S, Maldonado R, et al. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J Alzheimers Dis. 2013;35:847–858.
   PubMed Web of Science ®Google Scholar
• Area-Gomez E, de Groof A, Bonilla E, et al. A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease. Cell Death Dis. 2018;9:335.
   PubMed Web of Science ®Google Scholar
• Wang X, Zheng P, Huang G, et al. Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes. Clin Exp Med. 2018;18:473–480.
   PubMed Web of Science ®Google Scholar
• Xie W, Song X, Liu Z. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascul Pharmacol. 2018;109:17–26.
   PubMed Web of Science ®Google Scholar
• Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015;8:163–171.
   PubMed Web of Science ®Google Scholar
• Goto M, Furuta S, Yamashita S, et al. Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport. J Diabetes Investig. 2018;9:1261–1269.
   PubMed Web of Science ®Google Scholar
• Li Q, Li J, Liu Y, et al. Anagliptin prevents apoptosis of human umbilical vein endothelial cells by modulating NOX-4 signaling pathways. Biomed Pharmacother. 2018;103:1623–1631.
   PubMed Web of Science ®Google Scholar
• Isik AT, Soysal P, Yay A, et al. The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer’s disease. Diabetes Res Clin Pract. 2017;123:192–198.
   PubMed Web of Science ®Google Scholar
• Angelopoulou E, Piperi C. DPP-4 inhibitors: a promising therapeutic approach against Alzheimer’s disease. Ann Transl Med. 2018;6:255.
   PubMed Web of Science ®Google Scholar
• Kornelius E, Lin CL, Chang HH, et al. DPP-4 Inhibitor linagliptin attenuates Abeta-induced cytotoxicity through activation of AMPK in neuronal Cells. CNS Neurosci Ther. 2015;21:549–557.
   PubMed Web of Science ®Google Scholar
• Kosaraju J, Gali CC, Khatwal RB, et al. Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer’s disease. Neuropharmacology 2013;72:291–300.
   PubMed Web of Science ®Google Scholar
• Sheng B, Song B, Zheng Z, et al. Abnormal cleavage of APP impairs its functions in cell adhesion and migration. Neurosci Lett. 2009;450:327–331.
   PubMed Web of Science ®Google Scholar
• Jiang T, Jiang D, Zhang L, et al. Anagliptin ameliorates high glucose- induced endothelial dysfunction via suppression of NLRP3 inflammasome activation mediated by SIRT1. Mol Immunol. 2019;107:54–60.
   PubMed Web of Science ®Google Scholar
• Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006;1:3159–3165.
   PubMed Web of Science ®Google Scholar
• Jan AT, Azam M, Rahman S, et al. Perspective insights into disease progression, diagnostics, and therapeutic approaches in Alzheimer’s disease: a judicious update. Front Aging Neurosci. 2017;9:356.
   PubMed Web of Science ®Google Scholar
• Dai MH, Zheng H, Zeng LD, et al. The genes associated with early-onset Alzheimer’s disease. Oncotarget 2017;9:15132–15143.
   PubMedGoogle Scholar
• Sasaguri H, Nilsson P, Hashimoto S, et al. APP mouse models for Alzheimer’s disease preclinical studies. Embo J. 2017;36:2473–2487.
   PubMed Web of Science ®Google Scholar
• Crouch PJ, Harding SME, White AR, et al. Mechanisms of A beta mediated neurodegeneration in Alzheimer’s disease. Int J Biochem Cell Biol. 2008;40:181–198.
   PubMed Web of Science ®Google Scholar
• Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer’s disease. J Neurochem. 2012;120:419–429.
   PubMed Web of Science ®Google Scholar
• Cabezas-Opazo FA, Vergara-Pulgar K, Pérez MJ, et al. Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer’s Disease. Oxid Med Cell Longev. 2015;2015:509654.
   PubMed Web of Science ®Google Scholar
• Chiba Y, Yamakawa T, Tsuchiya H, et al. Effect of anagliptin on glycemic and lipid profile in patients with type 2 Diabetes Mellitus. J Clin Med Res. 2018;10:648–656.
   PubMedGoogle Scholar
• Carelli-Alinovi C, Misiti F. Erythrocytes as Potential Link between Diabetes and Alzheimer’s Disease. Front Aging Neurosci. 2017;9:276.
   PubMed Web of Science ®Google Scholar
• Salcedo I, Tweedie D, Li Y, et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol. 2012;166:1586–1599.
   PubMed Web of Science ®Google Scholar
• Hölscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J Endocrinol. 2014;221:T31–T41.
   PubMed Web of Science ®Google Scholar
• Fernandez CG, Hamby ME, McReynolds ML, et al. The role of APOE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer’s disease. Front Aging Neurosci. 2019;11:14.
   PubMed Web of Science ®Google Scholar